Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome
Jennifer W. Leiding,Tiphanie P. Vogel,Valentine G.J. Santarlas,Rahul Mhaskar,Madison R. Smith,Alexandre Carisey,Alexander Vargas-Hernández,Manuel Silva-Carmona,Maximilian Heeg,Anne Rensing-Ehl,Bénédicte Neven,Jérôme Hadjadj,Sophie Hambleton,Timothy Ronan Leahy,Kornvalee Meesilpavikai,Charlotte Cunningham-Rundles,Cullen M. Dutmer,Svetlana O. Sharapova,Mervi Taskinen,Ignatius Chua,Rosie Hague,Christian Klemann,Larysa Kostyuchenko,Tomohiro Morio,Akaluck Thatayatikom,Ahmet Ozen,Anna Scherbina,Cindy S. Bauer,Sarah E. Flanagan,Eleonora Gambineri,Lisa Giovannini-Chami,Jennifer Heimall,Kathleen E. Sullivan,Eric Allenspach,Neil Romberg,Sean G. Deane,Benjamin T. Prince,Melissa J. Rose,John Bohnsack,Talal Mousallem,Rohith Jesudas,Maria Marluce Dos Santos Vilela,Michael O’Sullivan,Jana Pachlopnik Schmid,Štěpánka Průhová,Adam Klocperk,Matthew Rees,Helen Su,Sami Bahna,Safa Baris,Lisa M. Bartnikas,Amy Chang Berger,Tracy A. Briggs,Shannon Brothers,Vanessa Bundy,Alice Y. Chan,Shanmuganathan Chandrakasan,Mette Christiansen,Theresa Cole,Matthew C. Cook,Mukesh M. Desai,Ute Fischer,David A. Fulcher,Silvanna Gallo,Amelie Gauthier,Andrew R. Gennery,José Gonçalo Marques,Frédéric Gottrand,Bodo Grimbacher,Eyal Grunebaum,Emma Haapaniemi,Sari Hämäläinen,Kaarina Heiskanen,Tarja Heiskanen-Kosma,Hal M. Hoffman,Luis Ignacio Gonzalez-Granado,Anthony L. Guerrerio,Leena Kainulainen,Ashish Kumar,Monica G. Lawrence,Carina Levin,Olaf Neth,Peter Olbrich,Alejandro Palma,Niraj C. Patel,Tamara Pozos,Kahn Preece,Saúl Oswaldo Lugo Reyes,Mark A. Russell,Yael Schejter,Christine Seroogy,Jan Sinclair,Effie Skevofilax,Daniel Suan,Daniel Suez,Paul Szabolcs,Helena Velasco,Klaus Warnatz,Kelly Walkovich,Austen Worth,Svetlana Aleshkevich,Luis M. Allende,T. Prescott Atkinson,Faranaz Atschekzei,Sezin Aydemir,Utku Aygunes,Vincent Barlogis,Ulrich Baumann,John Belko,Liliana Bezrodnik,Ariane Biebl,Lori Broderick,Nancy J. Bunin,Maria Soledad Caldirola,Martin Castelle,Fatih Celmeli,Louis-Marie Charbonnier,Talal A. Chatila,Deepak Chellapandian,Haluk Cokugras,Niall Conlon,Fionnuala Cox,Etienne Crickx,Buket Dalgic,Virgil ASH Dalm,Silvia Danielian,Nerea Dominguez-Pinilla,Tal Dujovny,Mikael Ebbo,Ahmet Eken,Brittany Esty,Alexandre Fabre,Alain Fischer,Mark Hannibal,Laura Huppert,Marc D. Ikeda,Stephen Jolles,Kent W. Jolly,Neil Jones,Maria Kanariou,Elif Karakoc-Aydiner,Theoni Karamantziani,Charikleia Kelaidi,Mary Keogan,Ayşenur Pac Kisaarslan,Ayca Kiykim,Adam Klocperk,Kosmas Kotsonis,Natalia Kuzmenko,Sylvie Leroy,Dimitra Lianou,Hilary Longhurst,Myriam Ricarda Lorenz,Patrick Maffucci,Ania Manson,Sarah Marchal,Marion Malphettes,Lia Furlaneto Marega,Andrea A. Mauracher,Kornvalee Meesilpavikai,Holly Miller,Joy Mombourquette,Noel G. Morgan,Anna Mukhina,Aladjidi Nathalie,Brigitte Nelken,David Nolan,Anna-Carin Norlin,Matias Oleastro,Alper Ozcan,Marlene Pasquet,José Roberto Pegler,Capucine Picard,Sophia Polychronopoulou,Pierre Quartier,Juan Francisco Quesada,Jan Ramakers,Katrina L. Randall,V. Koneti Rao,Allison Remiker,Geraldine Resin,Peter Richmond,Frederic Rieux-Laucat,Yulia Rodina,Pierre Rohrlich,Johnathan Sachs,Inga Sakovich,Christopher Santarlas,Sinan Sari,Gregory Sawicki,Uwe Schauer,Selma C. Scheffler Mendoza,Oksana Schvetz,Reinhold Ernst Schmidt,Klaus Schwarz,Anna Sediva,Kyle Sinclair,Mary Slatter,John Sleasman,Katerina Stergiou,Narissara Suratannon,Kay Tanita,Grace Thompson,Stephen Travis,Timothy Trojan,Maria Tsinti,Ekrem Unal,Luciano Urdinez,Felisa Vazquez-Gomez,Mariana Villa,Michael Weinrich,Mitchell J. Weiss,Benjamin Wright,Ebru Yilmaz,Radana Zachova,Yu Zhang,Mikko R.J. Seppänen,Troy R. Torgerson,Georgios Sogkas,Stephan Ehl,Stuart G. Tangye,Megan A. Cooper,Joshua D. Milner,Lisa R. Forbes Satter,Timi Martelius
DOI: https://doi.org/10.1016/j.jaci.2022.09.002
IF: 14.29
2023-04-01
Journal of Allergy and Clinical Immunology
Abstract:BACKGROUND: In 2014, germline signal transducer and activator of transcription (STAT) 3 gain-of-function (GOF) mutations were first described to cause a novel multisystem disease of early-onset lymphoproliferation and autoimmunity.OBJECTIVE: This pivotal cohort study defines the scope, natural history, treatment, and overall survival of a large global cohort of patients with pathogenic STAT3 GOF variants.METHODS: We identified 191 patients from 33 countries with 72 unique mutations. Inclusion criteria included symptoms of immune dysregulation and a biochemically confirmed germline heterozygous GOF variant in STAT3.RESULTS: Overall survival was 88%, median age at onset of symptoms was 2.3 years, and median age at diagnosis was 12 years. Immune dysregulatory features were present in all patients: lymphoproliferation was the most common manifestation (73%); increased frequencies of double-negative (CD4-CD8-) T cells were found in 83% of patients tested. Autoimmune cytopenias were the second most common clinical manifestation (67%), followed by growth delay, enteropathy, skin disease, pulmonary disease, endocrinopathy, arthritis, autoimmune hepatitis, neurologic disease, vasculopathy, renal disease, and malignancy. Infections were reported in 72% of the cohort. A cellular and humoral immunodeficiency was observed in 37% and 51% of patients, respectively. Clinical symptoms dramatically improved in patients treated with JAK inhibitors, while a variety of other immunomodulatory treatment modalities were less efficacious. Thus far, 23 patients have undergone bone marrow transplantation, with a 62% survival rate.CONCLUSION: STAT3 GOF patients present with a wide array of immune-mediated disease including lymphoproliferation, autoimmune cytopenias, and multisystem autoimmunity. Patient care tends to be siloed, without a clear treatment strategy. Thus, early identification and prompt treatment implementation are lifesaving for STAT3 GOF syndrome.
immunology,allergy